Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 24,695

Document Document Title
WO/2019/099711A1
The disclosure is directed to the use of a pharmaceutical product to accelerate recovery of adverse side-effects resulting from neurotoxin therapy for bladder dysfunction.  
WO/2019/095064A1
The present description relates to the use of a SRSF3 agent for regulating the function of a myeloid cell, such as a microglial cell and/or monocyte, for treating neurological conditions, cancers, bacterial infections and viral infection...  
WO/2019/099800A1
Trophic factor expressing monocyte cells derived from gene-edited induced pluripotent stem cells, methods for making and using.  
WO/2019/099823A1
Methods and mechanisms for treating and/or alleviating myotonic dystrophy type 1 (DM1 by editing the DMPK gene. Editing of the DMPK gene may take place in vivo, or may involve ex vivo correction followed by implantation of genome-correct...  
WO/2019/100053A1
Compositions and methods for modulating HIF-2α to meditate of hypoxia signaling in satellite cells and applications thereof for improving skeletal muscle generation and repair are provided. For example, methods of enhancing, increasing,...  
WO/2019/092251A1
The present disclosure relates to a BIN1 protein or a BIN1 nucleic acid sequence producing or encoding the same, for a use in the treatment of X-linked centronuclear myopathy. The present invention provides compositions and methods for t...  
WO/2018/225065A9
Novel aminoglycosides, represented by Formulae (e.g., a compound of Formula A, B, I, I*, III or III*, including compounds represented by Formula Ia, I**, I*a, I*b, IIIa, III**, III*a and, III*b), as defined in the instant specification, ...  
WO/2019/086407A1
The invention relates to the field of protein-dense liquid nutritional compositions for use in the treatment and/or prevention of a condition linked to loss of muscle mass and/or strength. Provided is a heat-treated liquid high-protein c...  
WO/2019/090085A1
Provided herein are compounds of formula (I), compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions. (Formula I).  
WO/2019/088159A1
The present application provides a substituted purine compound represented by formula (1) and a pharmaceutically acceptable salt thereof, which exhibit a TLR7-inhibiting effect and are useful for therapy, etc., of autoimmune diseases. [I...  
WO/2019/087280A1
The present invention provides a muscle-building composition or the like that has few side effects, is very safe, and enables efficient buildup of muscles. Disclosed are: a muscle-building composition that contains, as an active ingredie...  
WO/2019/085872A1
Disclosed are methods and compositions useful in preventing or treating a disease related to muscle wasting by using acidic fibroblast growth factor (aFGF).  
WO/2019/088010A1
The present invention provides a testosterone-containing transdermally administrable preparation having excellent testosterone cutaneous permeability and excellent physical properties. More specifically, the present invention provides a ...  
WO/2019/090078A1
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.  
WO/2019/090171A1
Provided herein are methods and compositions for increasing muscle strength, and for treating muscle wasting disorders, muscle degenerative disease, or exercise-induced weakness, and cancer.  
WO/2019/084499A1
Disclosed herein are methods and compositions for the treatment of facioscapulohumeral muscular dystrophy. In some cases, the methods and compositions involve the use of kinase inhibitors including Src, Syk, Abl, Tie, Flt, ErbB, Trk, PRK...  
WO/2019/082940A1
The purpose of the present invention is to provide a medicament containing as an active ingredient a compound having ryanodine inhibitory activity, in particular, RyR1 inhibitory activity. Provided is an agent for treating or preventing ...  
WO/2019/077810A1
Provided is an agent or composition useful for the proliferation of myocytes, etc. The agent or composition comprises component (A) which is at least one member selected from acteoside, echinacoside and salts thereof and component (B) wh...  
WO/2019/077149A1
The invention relates to a pharmaceutical composition for targeting drug delivery including gene delivery to regenerating muscle tissue, comprising at least a therapeutic drug or gene, associated to a syncytin protein, and its use in the...  
WO/2019/079596A1
The present disclosure relates to methods and compositions for treating immune-mediated diseases. In some aspects, the disclosure relates to methods for treating immune-mediated diseases by administering an EHMT2 inhibitor in combination...  
WO/2019/077258A1
The present invention relates to the field of oil-in-water emulsions and more particularly to oil-in-water emulsions containing essential oils and formulated without a surfactant or any other substitute substance.  
WO/2019/078711A1
The present invention relates to the use of an agent that inhibits POH1 to treat a patient suffering from or at risk of developing muscle degeneration. The invention arises from the discovery that POH1 regulates PABPN1 protein and thus o...  
WO/2019/078263A1
The present invention addresses the problem of providing a method for easily and efficiently preparing a functional and matured neuromuscular junction (NMJ) in vitro. This problem is solved by a method for producing an artificial neuromu...  
WO/2019/071353A1
A method of reducing glutamate efflux from skeletal muscle by inhibiting system Xc- activity is provided. The method is useful for the treatment of statin-induced myalgia. Pharmaceutical compositions useful to treat statin-induced myalgi...  
WO/2019/073507A1
Provided is a medicinal composition for preventing and/or treating amyotrophic lateral sclerosis (ALS), said composition containing a plexin A1 antagonist.  
WO/2019/068888A1
The present invention relates to the treatment of subjective tinnitus. More precisely, it concerns the administration of botulinum toxin into the scalp, neck and face muscles, especially in the temporalis muscle, of patients suffering fr...  
WO/2019/071147A1
The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDClL, RFPL2, CC...  
WO/2019/068604A1
The present invention relates to 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2 - b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of spinal muscular atrophy (SMA), its pharmaceutical composition to be...  
WO/2019/071144A1
The present invention relates to compositions and methods of inhibiting p38 kinase to reduce gene and protein expression of DUX4 and downstream genes regulated by DUX4. The present invention further relates to methods for treating patien...  
WO/2019/067979A1
The present disclosure relates to methods of treating Duchenne's Muscular Dystrophy by administering an antisense oligonucleotide that induces exon skipping and a non-steroidal anti- inflammatory compound.  
WO/2019/065928A1
The present invention addresses the problem of providing a compound for prophylaxis and/or treatment of inflammatory diseases of the central nervous system, or a pharmacologically acceptable salt thereof. Provided is a compound represent...  
WO/2019/067981A1
The present disclosure relates to methods of treating Duchenne's Muscular Dystrophy by administering an antisense oligonucleotide that induces exon skipping and a non-steroidal antiinflammatory compound.  
WO/2019/065791A1
Provided is a compound which has an MAGL inhibitory effect and is expected to be useful as a prophylactic or therapeutic agent for neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Hutchinson's disease, amyotrop...  
WO/2019/067975A1
The present disclosure relates to methods of treating Duchenne's Muscular Dystrophy by administering an antisense oligonucleotide that induces exon skipping and a non-steroidal anti- inflammatory compound.  
WO/2019/062662A1
Disclosed are a substituted pyrimidine piperazine compound of Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and a pharmaceuti...  
WO/2019/060297A1
Described herein are methods for mitochondrial transplantation wherein old, damaged, or mutated mitochondria are replaced with young, undamaged, or non-mutated mitochondria. The old, damaged, or mutated mitochondria can also be replaced ...  
WO/2019/059973A1
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.  
WO/2019/058132A1
This invention relates to compounds that are inhibitors of the CDK12 kinase. The compounds are useful in the treatment of disorders mediated by CDK12 kinase including myotonic dystrophy type 1 (DM1) and other disorders caused by the gene...  
WO/2019/055832A1
Provided herein are compounds of Formula (I) and (II) and their salts, and compositions comprising such compounds that are useful for useful for modulating neutral sphingomyelinase 2 (n-SMase2) in cells. Also disclosed herein are methods...  
WO/2019/054106A1
A suppressor of extracellular matrix production by epidermal growth factor receptor (EGFR)-expressing cells, said suppressor comprising an EGFR inhibitor as an active ingredient.  
WO/2019/054430A1
The purpose of the present invention is to provide a compound having an anti-inflammatory action, a pharmacologically acceptable salt thereof, etc. A solving means of the present invention is a compound of general formula (1) or a pharma...  
WO/2019/055687A1
In one aspect, the disclosure relates to methods and compositions for treatment of cancer cachexia. In a further aspect, the composition is a pharmaceutical composition comprising a class l/IIB HDAC inhibitor and an androgen. In a still ...  
WO/2019/055536A1
The present invention features compositions and methods that enhance cell extravasation and/or muscle cell fusion, and methods for identifying genes that enhance or inhibit extravasation and muscle cell fusion. One aspect of the present ...  
WO/2019/054427A1
The present invention addresses the problem of providing a compound having an anti-inflammatory effect, a pharmacologically acceptable salt thereof, etc. The means for solution according to the present invention is a compound represented...  
WO/2019/050923A1
The disclosure is directed to methods of treating subjects exposed to nerve agents with dantrolene, or a pharmaceutically acceptable salt thereof.  
WO/2019/046903A1
The present disclosure provides a method of increasing muscle mass in a subject, the method comprising administering to the subject follistatin or a functional fragment thereof for a period of time and in an amount sufficient to effect a...  
WO/2019/046251A1
The disclosure is directed to pharmaceutical compositions comprising of Tizanidine or a pharmaceutically acceptable salt thereof which controllably modulate the onset of at least one secondary effect associated with Tizanidine administra...  
WO/2019/044788A1
The purpose of the present invention is to provide a topical dermatological composition capable of easily improving the body's ability to balance for ordinary non-athletes who do not actively perform everyday exercise, such as housewives...  
WO/2019/044894A1
The present invention addresses the problem of providing a compound having strong conjugating activity with respect to a modified collagen, a use of the compound as a modified collagen test drug and research reagent, and a composition co...  
WO/2019/041361A1
A compound of Formula (I), pharmaceutically acceptable salts thereof, and individual enantiomers or diastereomers thereof are disclosed. Compositions and methods useful for treatment or suppression of diseases, developmental delays and s...  

Matches 1 - 50 out of 24,695